Clinical Scorecard: Tumor Microenvironments: Mechanisms of Immune Exclusion and Suppression, Spatial Biomarkers, and Strategies for Therapeutic Intervention
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with solid tumors exhibiting immune exclusion or suppression, particularly those resistant to immune checkpoint inhibitors.
Care Setting
Key Highlights
Resistant TMEs are dynamic ecosystems rather than static histologic phenotypes.
Guideline-Based Recommendations
Diagnosis
Management
Consider combination therapies targeting stromal and immune components, such as those involving CAFs and myeloid cells, to overcome resistance.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Therapeutic strategies should focus on rewiring the TME, including targeting CAFs and myeloid populations, to enhance immune response.
Clinical Best Practices
Integrate spatially informed biomarker systems in clinical decision-making, particularly for patient stratification.
